Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 2/20 | 0.48 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.48 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.48 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.48 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.48 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.48 |
| ▸ | ATP1B3 | P54709 | 3/20 | 0.48 |
| ▸ | FXYD2 | P54710 | 3/20 | 0.48 |
| ▸ | ATP1A4 | Q13733 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2054165 | 1.00 | MAPKAPK2 (0.56) | MAPKAPK2KDM4EGAAHPGDKDM4C | |
| SCHEMBL18448722 | 0.83 | FFAR2 (0.57) | MAPKAPK2KDM4EHPGDHSD17B10JAK2 | |
| SCHEMBL30765607 | 0.80 | GPR55 (0.51) | MAPKAPK2HPGDHSD17B10JAK2JAK3 | |
| SCHEMBL5981398 | 0.80 | KDM4E (0.56) | KDM4EGAAHPGDHTR7ATP1A1 | |
| SCHEMBL10594962 | 0.80 | KDM4E (0.56) | KDM4EGAAHPGDHTR7ATP1A1 | |
| SCHEMBL23780413 | 0.80 | ALDH1A1 (0.54) | MAPKAPK2KDM4EHPGDJAK2JAK3 | |
| SCHEMBL23291896 | 0.80 | ALDH1A1 (0.54) | MAPKAPK2KDM4EHPGDJAK2JAK3 | |
| SCHEMBL23780427 | 0.78 | SMN1; SMN2 (0.51) | KDM4EHPGDHSD17B10ALDH1A1GPR55 | |
| SCHEMBL23780425 | 0.78 | SMN1; SMN2 (0.51) | KDM4EHPGDHSD17B10ALDH1A1GPR55 | |
| SCHEMBL23291971 | 0.76 | HDAC3 (0.41) | MAPKAPK2KDM4EHPGDHSD17B10JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190177707-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2019-06-13 | — | — | US | claimed |
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-03-21 | — | — | US | claimed |
| WO-2017176792-A1 | METHODS OF PREVENTING OR REDUCING A FIBROTIC RESPONSE USING CSF 1R INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-10-12 | — | — | WO | claimed |
| US-12286653-B2 | Carboxyesterase polypeptides for amide coupling | CODEXIS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| US-20210238565-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2021-08-05 | — | — | US | disclosed |
| US-11015180-B2 | Carboxyesterase polypeptides for amide coupling | CODEXIS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| EP-3724325-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | Codexis, Inc. (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019118557-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | CODEXIS, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-20190177707-A1 | CARBOXYESTERASE POLYPEPTIDES FOR AMIDE COUPLING | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2019-06-13 | — | — | US | disclosed |
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2017176792-A1 | METHODS OF PREVENTING OR REDUCING A FIBROTIC RESPONSE USING CSF 1R INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-9115404-B2 | Polynucleotides for medical use | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN BERLIN-BUCH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-20120277281-A1 | POLYNUCLEOTIDES FOR MEDICAL USE | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-11-01 | — | — | US | disclosed |
| US-7598272-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| US-7511047-B2 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2009-03-31 | — | — | US | disclosed |
| US-20070161635-A1 | Kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2007-07-12 | — | — | US | disclosed |
| US-20060270687-A1 | Kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-11-30 | — | — | US | disclosed |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2006-10-26 | — | — | US | disclosed |
| US-7122550-B2 | Protein kinase inhibitors | CYTOPIA PTY LTD (AU) | 2006-10-17 | — | — | US | disclosed |
| US-20060148824-A1 | Protein kinase inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | CSF1R, CSF3R, CD209 | MAPKAPK2 1670/4885KDM4E 1634/4885GAA 1599/4885 |
| US-20060270687-A1 | Kinase inhibitors | MAP3K20, MAP3K1, MAP3K19 | MAPKAPK2 26/4885KDM4E 1738/4885GAA 875/4885 |
| US-20060241112-A1 | Such as n-(4-fluorobenzyl)-6-(4-methyl-1H-imidazol-1-yl)pyrazin-2-amine; protein kinase associated disease states | MAP4K2, MAP4K5, MAP4K4 | MAPKAPK2 27/4885KDM4E 1505/4885GAA 2100/4885 |
| US-20060148824-A1 | Protein kinase inhibitors | MAP3K20, MAP4K2, MAP3K1 | MAPKAPK2 24/4885KDM4E 1981/4885GAA 2073/4885 |
| US-20070161635-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K10 | MAPKAPK2 24/4885KDM4E 2364/4885GAA 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.